Novo Nordisk A/S is focusing on novel diabetes R&D as its blockbuster drug Ozempic faces emerging competition, even as Ozempic sales made up for the firm’s struggling obesity franchise during the second quarter.
While the Danish firm grapples with manufacturing issues for its highly in-demand obesity drug Wegovy (semaglutide injection 2.4mg), its older strength version of the GLP-1 agonist, Ozempic, is shoring up sales in diabetes
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?